BOURNE BRIEF: 2025 NICA Conference Takeaways
Key Take-Aways 2025 NICA Conference
The Bourne Partners team recently attended the 2025 National Infusion Center Association (NICA) Annual Conference to meet with executives and investors in the home and alternate site infusion therapy space. We view home and alternate site infusion therapy as one of the most attractive verticals in healthcare services today with growth driven by therapeutic innovation, the shift towards lower-cost settings of care, and patient preferences. Also, the home and alternate site infusion therapy space continues to be highly fragmented. So, we see an opportunity for meaningful economies of scale to be gained through mergers and acquisitions.
However, there are also unknowns. For instance, we heard discussions about the potential re-emergence of white-bagging mandates by health plans and uncertainty about drug pricing under the Inflation Reduction Act. Also, more recently, the Trump administration also issued an executive order to implement a “Most Favored Nations” policy for drug pricing. Based on our conversations, we believe that home and alternate site infusion therapy providers derive most of their profitability from the margin on the drugs that they administer — making much less on pharmacy services or nursing care. Accordingly, we are actively monitoring any potential changes to the drug pricing environment.
In the dynamic healthcare industry, staying ahead of trends is essential for informed decision marking and seizing opportunities. Please contact our research team at research@bourne-partners.com, our Head of Research Don Hooker, or our healthcare services investment banking team at aolson@bourne-partners.com for more information.
Click here to view this report in its entirety.